Pomdoctor Valuation Multiples

Discover revenue and EBITDA valuation multiples for Pomdoctor and similar public comparables like MedTech Solutions, CMON, Outdoorzy, Xcel Brands and more.

Pomdoctor Overview

About Pomdoctor

Pomdoctor Ltd is an online medical services platform for chronic diseases in China. With a focus on chronic disease management and pharmaceutical services, its business model forms a one-stop platform for medical services, which organically connects patients to doctors and pharmaceutical products. Its experience in tackling chronic diseases can be traced back to the launch of its platform on mobile devices. The company operates in two segments: Internet hospital, and Pharmaceutical supply chain. The majority of revenue is derived from the Pharmaceutical supply chain segment.


Founded

2010

HQ

China

Employees

154

Website

7lk.com

Financials (FY)

Revenue: $59M
EBITDA: ($17M)

EV

$74M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Pomdoctor Financials

Pomdoctor reported last fiscal year revenue of $59M and negative EBITDA of ($17M).

In the same fiscal year, Pomdoctor generated $8M in gross profit, ($17M) in EBITDA losses, and had net loss of ($32M).


Pomdoctor P&L

In the most recent fiscal year, Pomdoctor reported revenue of $59M and EBITDA of ($17M).

Pomdoctor is unprofitable as of last fiscal year, with gross margin of 13%, EBITDA margin of (29%), and net margin of (53%).

See analyst estimates for Pomdoctor
Last FY202320242025202620272028
Revenue$59M$45M$51M$59M
Gross Profit$8M$6M$7M$8M
Gross Margin13%13%14%13%
EBITDA($17M)($3M)($4M)($17M)
EBITDA Margin(29%)(8%)(7%)(29%)
EBIT Margin(29%)(7%)(7%)(29%)
Net Profit($32M)($22M)($21M)($32M)
Net Margin(53%)(48%)(42%)(53%)
Net Debt$66M---

Financial data powered by Morningstar, Inc.

Pomdoctor Stock Performance

Pomdoctor has current market cap of $8M, and enterprise value of $74M.


Pomdoctor's stock price is $1.02.

Pomdoctor has an EPS (earnings per share) of $-4.23.

See more trading valuation data for Pomdoctor
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$74M$8M4.7%---$-4.23

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Pomdoctor Valuation Multiples

Pomdoctor trades at 1.2x EV/Revenue multiple, and (4.2x) EV/EBITDA.

See NTM and 2027E valuation multiples for Pomdoctor

Pomdoctor Financial Valuation Multiples

As of August 15, 2026, Pomdoctor has market cap of $8M and EV of $74M.

Pomdoctor has a P/E ratio of (0.2x).

Last FY202320242025202620272028
EV/Revenue1.2x1.6x1.4x1.2x
EV/EBITDA(4.2x)(21.6x)(20.5x)(4.2x)
EV/EBIT(4.3x)(24.4x)(21.3x)(4.3x)
EV/Gross Profit9.5x12.8x10.4x9.5x
P/E(0.2x)(0.4x)(0.4x)(0.2x)
EV/FCF(3.3x)(10.8x)(30.7x)(3.3x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Pomdoctor Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Pomdoctor Margins & Growth Rates

In the most recent fiscal year, Pomdoctor reported gross margin of 13%, EBITDA margin of (29%), and net margin of (53%).

See estimated margins and future growth rates for Pomdoctor

Pomdoctor Margins

Last FY20242025202720282029
Gross Margin13%14%13%
EBITDA Margin(29%)(7%)(29%)
EBIT Margin(29%)(7%)(29%)
Net Margin(53%)(42%)(53%)
FCF Margin(37%)(5%)(37%)

Pomdoctor Growth Rates

23/2424/2526/2727/2828/29
Revenue Growth12%17%
Gross Profit Growth23%10%
EBITDA Growth6%386%
EBIT Growth15%398%
Net Profit Growth(1%)48%
FCF Growth(65%)825%

Data powered by FactSet, Inc. and Morningstar, Inc.

Pomdoctor Operational KPIs

Pomdoctor's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.2M for the same period.

Access forward-looking KPIs for Pomdoctor
Last FY202320242025202620272028
Revenue per Employee$0.4M---
Opex per Employee$0.2M---
S&M Expenses to Revenue24%14%16%24%
G&A Expenses to Revenue15%4%3%15%
R&D Expenses to Revenue3%1%1%3%
Opex to Revenue42%19%21%42%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Pomdoctor Competitors

Pomdoctor competitors include MedTech Solutions, CMON, Outdoorzy, Xcel Brands, Giglio, Wellgistics Health, Digital Brands Group, Westwing Brasil, Sweden BuyersClub and Kumulus Vape.

Most Pomdoctor public comparables operate across Pharmacies, Consumer E-commerce and Vertical E-commerce.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
MedTech Solutions74.8x-(9.0x)-
CMON0.9x-(0.5x)-
Outdoorzy2.7x-(93.5x)-
Xcel Brands4.8x3.7x(2.1x)(18.7x)
Giglio0.1x0.1x(2.4x)(2.2x)
Wellgistics Health----
Digital Brands Group1.9x-(0.5x)-
Westwing Brasil(0.5x)-(14.4x)-

This data is available for Pro users. Sign up to see all Pomdoctor competitors and their valuation data.

Start Free Trial

Pomdoctor VC Funding History

Before going public, Pomdoctor raised $148M in total equity funding, across 2 rounds.


Pomdoctor Funding Rounds

DateStageInvestorsRaisedValuationRev. MultipleDeal Summary
Jan-16Series B-$100M-7LeKang (7lk), founded in 2011 and headquartered in Guangzhou, China, operates an online B2C pharmacy platform complemented by nine offline stores, focusing on pharmaceutical e-commerce and expanding into mobile healthcare services. The company completed a $100 million Series B funding round in late 2015 or early 2016 from undisclosed investors, following a RMB300 million Series A in January 2015. Proceeds were allocated to mobile healthcare services, expanding its doctors' network, patient subsidies, recruiting doctors, and paying service fees. In 2015, 7LeKang recorded revenues of RMB1 billion (approximately US$153 million), with over 10 million registered users. Earlier data shows online pharmacy sales of RMB771 million in 2014, and monthly sales of RMB38 million in September 2015 across platforms including its own site (RMB10 million), Tmall Drugstore (RMB21 million), and JD.com (RMB7 million). The company launched the 'Dabai Yunzhen' mobile health management app in 2015 for doctor-patient management. 7LeKang continued raising capital post-Series B, achieving a total of $148.37M across 9 rounds, reaching Series E-III by September 2021.
Jan-15Series A-$48M-7LeKang, founded in 2011 and headquartered in Guangzhou, China, operates an online pharmacy platform and nine offline stores, providing B2C pharmaceutical sales and later expanding into mobile healthcare services. The company rebranded later to PomDoctor (石榴云医) and continued operations, raising total funding of approximately $148M across nine rounds up to Series E-III in 2021. In 2015, 7LeKang achieved annual revenues of RMB1 billion (US$153 million), with over 10 million registered users, reflecting strong growth in its online pharmacy business. Monthly sales in September 2015 reached RMB38 million across platforms including its own site (RMB10 million), Tmall Drugstore (RMB21 million), and JD.com (RMB7 million). The firm launched the 'Dabai Yunzhen' mobile health management app in August 2015 for doctor-patient management. Investors across later rounds include Focus Media, Step Venture Capital, SND Financial Holdings, and others, totaling 20 backers. 7LeKang was among China's early online pharmacy license holders, competing in the O2O healthcare e-commerce space amid rapid sector growth.

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Pomdoctor

When was Pomdoctor founded?Pomdoctor was founded in 2010.
Where is Pomdoctor headquartered?Pomdoctor is headquartered in China.
How many employees does Pomdoctor have?As of today, Pomdoctor has over 154 employees.
Is Pomdoctor publicly listed?Yes, Pomdoctor is a public company listed on Nasdaq.
What is the stock symbol of Pomdoctor?Pomdoctor trades under POM ticker.
When did Pomdoctor go public?Pomdoctor went public in 2025.
Who are competitors of Pomdoctor?Pomdoctor main competitors include MedTech Solutions, CMON, Outdoorzy, Xcel Brands, Giglio, Wellgistics Health, Digital Brands Group, Westwing Brasil, Sweden BuyersClub, Kumulus Vape.
What is the current market cap of Pomdoctor?Pomdoctor's current market cap is $8M.
What is the current revenue of Pomdoctor?Pomdoctor's last fiscal year revenue is $59M.
What is the current EV/Revenue multiple of Pomdoctor?Current revenue multiple of Pomdoctor is 1.2x.
Is Pomdoctor profitable?No, Pomdoctor is not profitable.
How many companies Pomdoctor has acquired to date?Pomdoctor hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Pomdoctor has invested to date?Pomdoctor hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Pomdoctor

Lists including Pomdoctor

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial